ROCKVILLE, Md., Feb. 3, 2016 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a clinical stage company focused on
developing therapeutics to protect the gut microbiome, announced
today that Jeffrey Riley, CEO, is
scheduled to present at the BIO CEO & Investor Conference on
Monday, February 8, 2016, at
8:30 a.m. (ET) at the Waldorf Astoria
(Conrad room) in New York.
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the internet at
https://www.veracast.com/webcasts/bio/ceoinvestor2016/83103495204.cfm.
After the presentation, a replay will be archived and accessible
for 90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic
Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company
developing therapeutics to protect the microbiome while targeting
pathogen-specific diseases. The Company's lead candidates in Phase
2 development include: (1) SYN-004 which is designed to protect the
gut microbiome from the effects of certain commonly used
intravenous (IV) antibiotics for the prevention of C. difficile
infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010
which is intended to reduce the impact of methane producing
organisms in the gut microbiome to treat an underlying cause of
irritable bowel syndrome with constipation (IBS-C). In
collaboration with Intrexon Corporation (NYSE: XON), the Company is
developing a preclinical stage monoclonal antibody for the
prevention and treatment of Pertussis, and discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2016-bio-ceo--investor-conference-300214062.html
SOURCE Synthetic Biologics, Inc.